Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study.
Sijin Li, Yawen Zhang, Haiying Li, Zeyang He, An Li, Jiao Yan, Daocheng Li
{"title":"Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study.","authors":"Sijin Li, Yawen Zhang, Haiying Li, Zeyang He, An Li, Jiao Yan, Daocheng Li","doi":"10.1515/med-2024-1106","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study compared the efficacy and safety of carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel in treating locally advanced cervical cancer (LACC).</p><p><strong>Methods: </strong>A total of 48 patients were enrolled between January 2019 and December 2022 and randomly assigned to the experimental group (carboplatin + arsenic trioxide, <i>n</i> = 24) or control group (carboplatin + docetaxel, <i>n</i> = 24). The clinical efficacy, adverse reactions, and serological markers were analyzed.</p><p><strong>Results: </strong>There was no significant difference in baseline characteristics or total effective rates between the two groups (72.22% vs 68.42%, <i>P</i> > 0.05). Both groups showed significant reductions in serum squamous cell carcinoma antigen levels after chemotherapy (<i>P</i> < 0.05), but no significant difference was observed between groups (6.00 ± 11.36 ng/mL vs 8.42 ± 12.17 ng/mL, <i>P</i> > 0.05). Additionally, there was no significant difference in the incidence of adverse reactions (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>Arsenic trioxide combined with carboplatin as a preoperative neoadjuvant chemotherapy for LACC is not worse than docetaxel combined with carboplatin in terms of short-term efficacy and safety during the treatment of LACC.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"19 1","pages":"20241106"},"PeriodicalIF":1.7000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635763/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2024-1106","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This study compared the efficacy and safety of carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel in treating locally advanced cervical cancer (LACC).
Methods: A total of 48 patients were enrolled between January 2019 and December 2022 and randomly assigned to the experimental group (carboplatin + arsenic trioxide, n = 24) or control group (carboplatin + docetaxel, n = 24). The clinical efficacy, adverse reactions, and serological markers were analyzed.
Results: There was no significant difference in baseline characteristics or total effective rates between the two groups (72.22% vs 68.42%, P > 0.05). Both groups showed significant reductions in serum squamous cell carcinoma antigen levels after chemotherapy (P < 0.05), but no significant difference was observed between groups (6.00 ± 11.36 ng/mL vs 8.42 ± 12.17 ng/mL, P > 0.05). Additionally, there was no significant difference in the incidence of adverse reactions (P > 0.05).
Conclusion: Arsenic trioxide combined with carboplatin as a preoperative neoadjuvant chemotherapy for LACC is not worse than docetaxel combined with carboplatin in terms of short-term efficacy and safety during the treatment of LACC.
期刊介绍：
Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
